Navigation Links
Neurocrine Biosciences Reports Third Quarter 2008 Results
Date:10/28/2008

The trial contains standard assessments of safety, tolerability and pharmacokinetics. The clinical endpoints reflect change in symptom frequency and severity and the data should be available later in 2008.

GSK has advanced a novel lead CRF1 receptor antagonist compound, 561679, into a Phase II trial in patients with major depressive disorder. Enrollment of approximately 150 subjects is anticipated in this 6-week randomized, double-blind, placebo-controlled trial.

In addition to the two compounds listed above, GSK has also successfully completed a Phase I single dose-escalating clinical trial with a third CRF1 compound, 586529, for the treatment of anxiety and depression.

Urocortin 2 for Congestive Heart Failure (CHF) Continues Preclinical Evaluation

Initiation of longer term (up to 72 hours in duration) Phase II clinical trials of urocortin 2 are awaiting additional preclinical data. The Company has identified five preclinical studies necessary to support the longer period of infusion in the clinical program. Two of these five preclinical studies were successfully completed by July 2008. The two completed studies were non- GLP toxicology and safety assessment studies over 14 days of continuous infusion in distinct species models. The favorable results of these studies now await confirmation in the GLP preclinical studies anticipated later in 2008.

Indiplon Update

The Company met with the FDA in July for an end of review meeting related to the December 12, 2007 approvable letter for indiplon capsules. The FDA meeting focused on the three additional requirements outlined in the approvable letter. After exchange of correspondence regarding meeting minutes, the Company is awaiting the FDA's final version of these minutes to determine the next course of action related to indiplon capsules.

Conference Call and Webcast Today at 5:00 p.m. Eastern Daylight Time

Neurocrine will hold a live conference call and webcast tod
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Webcast Alert: Neurocrine Announces 3Q 08 Financial Results
2. Neurocrine Biosciences to Present at the Oppenheimer 19th Annual Healthcare Conference
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2008 Financial Results
4. Neurocrine Biosciences to Present at the UBS Global Life Sciences Conference
5. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
6. Neurocrine Biosciences Reports Second Quarter 2008 Results
7. Neurocrine Biosciences Announces Conference Call and Webcast To Present Second Quarter 2008 Financial Results
8. Neurocrine Biosciences to Present at the 2008 Citi Investment Research Global Health Care Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2008 Financial Results
10. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year End 2007 Financial Results
11. Neurocrine Announces Appointment of Kevin Gorman, Ph.D., as President and Chief Executive Officer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... 2014  Spherix Incorporated (Nasdaq: SPEX) -- an intellectual property ... of intellectual property, announced today that the Markman ... in the U.S. District Court for the Northern ... been rescheduled for November 10, 2014.  This hearing ... Court Order setting the Markman date was received ...
(Date:10/1/2014)... Jolla, Calif. (PRWEB) September 30, 2014 ... announced the initial round of grants for the ... an undertaking that aims to develop and revolutionize ... circuit functions of the human brain. This first ... for fiscal year 2014 was allocated to more ...
(Date:10/1/2014)... Centreville, VA (PRWEB) October 01, 2014 ... the Diagnostic, Clinical Therapeutics, Healthcare IT, and Laboratory Testing ... and regulatory positions at the director level and above ... payers struggling to stay on top of rapid breakthroughs ... a result, many diagnostic companies have been forced to ...
(Date:10/1/2014)... Industry leaders from retail pharmacies to ... theme, ,Commercial Opportunities in the Era of Reform, from ... Elsevier , a world-leading provider of scientific, technical and ... of some of the industry,s most prominent healthcare leaders ... in the future. The Elsevier Healthcare and ...
Breaking Biology Technology:Markman Hearing Date for VTech and Uniden Litigation Now Set for November 10, 2014 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 2NIH Awards 15 Grants to CHI Members for BRAIN Initiative Research 3Slone Partners Meets Growing Demand as Industry Focuses on Reimbursement & Regulation 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 2Elsevier Healthcare and Pharmaceutical Economics Conference 2014 To Convene Industry Leaders to Discuss Top Healthcare Business Issues 3
... on Custom Medical Devices, SOUTH ORANGE, N.J., Aug. ... -- Vincent J. Capricci, 56, is a former public,school ... avid,hunter, golfer and fisherman. After minor surgery a few ... his ankle joint.,He was out of work for nine ...
... has appointed FBI Supervising Special Agent (Ret.) Dr. Philip Hayden as its ... ... (Business Wire EON) August 18, 2008 -- Dr. Hayden comes to ... Dr. Philip Hayden has spent years involved in many aspects of law ...
... Includes $10 Million in Upfront Fees and Milestones ... INC.,(OTC Bulletin Board: ACCP) and Milestone Biosciences, LLC ... agreement under which,Milestone will market Access, proprietary product ... a company recently started by former,executives and sales ...
Cached Biology Technology:FDA Gets Knocked Out in Endotec, Inc. Ruling 2FDA Gets Knocked Out in Endotec, Inc. Ruling 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 2 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 3 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis 4Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 2Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America 3
(Date:10/2/2014)... 2014 The global genomics market was valued ... grow at a CAGR of over 12.0% from 2013 ... expansion of genomics applications, and advancements in existing technologies ... to invest in this market. Next Generation Sequencing (NGS) ... a high growth area for the global genomics market. ...
(Date:10/1/2014)... hope to take a healthy salad up a level ... breast cancer in leafy greens. , "In the long ... by eating the salad or making a pill from ... biomedical engineering at Case Western Reserve School of Medicine ... Komen breast cancer organization is funding the research with ...
(Date:10/1/2014)... , October 1, 2014 ... in the life science field  The ... come and go over the years. Some are ... Photon upconversion is a novel detection technology that ... years. Now, finally, this technology is becoming commercially ...
Breaking Biology News(10 mins):Genomics Market by Products - [Instruments (NGS platform, Microarray, RT-PCR), Consumables (Genechips, Reagents for DNA Extraction & Purification, Sequencing)], Services (Sequencing & Microarray Services, and Software) - Global Forecast to 2018 2Scientists wield plant viruses against deadly human disease 2Scientists wield plant viruses against deadly human disease 3First-of-a-kind Solution for Utilizing Photon Upconversion 2
... noses and Microsoft Windows, infamous blue screen of death ... being made by a new research report appearing online ... Specifically, scientists now know exactly why we sneeze, what ... not work properly. Much like a temperamental computer, our ...
... Olympic athletes may be the best trained and physically ... susceptible to back pain. BackPainRelief.net is releasing an infographic ... injuries can be avoided. (Photo: ... for a number of injuries, and back pain is ...
... (July 30, 2012) When the longest cells in the body ... is no easy task. This is in part because these ... one meter in adult humans which is a lot ... order to reach the "command center" of the cell,s nucleus. ...
Cached Biology News:Allergies? Your sneeze is a biological response to the nose's 'blue screen of death' 2Backpainrelief.net Tackles Sports Injuries with Infographic 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 3
... of Class II Biological Safety Cabinets ... to the world's highest safety standards. ... cabinets cannot be adjusted out of ... noise and arm rest ensure safety ...
... The Holten MaxiSafe 2010 Class II ... ergonomical working condition of comfort while ... efficiency and performance.,Refined operator, environment and ... both exhausted and recirculated air.,Bottom filters ...
... is designed for paramagnetic bead precipitation from ... PCR plates with no additional accessories. The ... a standard SBS 96-well microplate footprint. The ... guarantees easy and fast (as little as ...
... Minidizer is a personal desktop unit ideal for ... requirements. , Rotation speed set at 12 ... 80o C , Bottle capacity of four ... 15 ml conical ,plastic bottles , Consistent, ...
Biology Products: